Gebasaxturev IV + Gebasaxturev ITu + Pembrolizumab
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Melanoma
Conditions
Advanced/Metastatic Melanoma
Trial Timeline
Jun 5, 2020 → Jul 12, 2023
NCT ID
NCT04152863About Gebasaxturev IV + Gebasaxturev ITu + Pembrolizumab
Gebasaxturev IV + Gebasaxturev ITu + Pembrolizumab is a phase 2 stage product being developed by Merck for Advanced/Metastatic Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04152863. Target conditions include Advanced/Metastatic Melanoma.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Melanoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04152863 | Phase 2 | Terminated |
Competing Products
20 competing products in Advanced/Metastatic Melanoma